2,373 Shares in Cencora, Inc. $COR Bought by NewEdge Wealth LLC

NewEdge Wealth LLC bought a new position in shares of Cencora, Inc. (NYSE:COR) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,373 shares of the company’s stock, valued at approximately $671,000.

Several other large investors also recently bought and sold shares of COR. Accent Capital Management LLC boosted its position in shares of Cencora by 36.1% in the 4th quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock worth $38,000 after buying an additional 30 shares in the last quarter. MCF Advisors LLC increased its holdings in Cencora by 11.0% during the 4th quarter. MCF Advisors LLC now owns 303 shares of the company’s stock valued at $102,000 after acquiring an additional 30 shares in the last quarter. CYBER HORNET ETFs LLC increased its holdings in Cencora by 6.8% during the 4th quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock valued at $164,000 after acquiring an additional 31 shares in the last quarter. Steph & Co. raised its position in Cencora by 23.5% during the first quarter. Steph & Co. now owns 168 shares of the company’s stock worth $53,000 after acquiring an additional 32 shares during the last quarter. Finally, Beacon Pointe Advisors LLC raised its position in Cencora by 1.1% during the fourth quarter. Beacon Pointe Advisors LLC now owns 3,492 shares of the company’s stock worth $1,180,000 after acquiring an additional 37 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on COR. Royal Bank Of Canada began coverage on shares of Cencora in a research report on Wednesday. They issued a “sector perform” rating and a $330.00 price target on the stock. Barclays cut their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Citigroup reaffirmed a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. William Blair began coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating on the stock. Finally, UBS Group raised their price target on Cencora from $412.00 to $430.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $370.85.

Insider Buying and Selling

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.38% of the company’s stock.

Cencora Price Performance

Cencora stock opened at $317.89 on Friday. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock has a market capitalization of $60.66 billion, a P/E ratio of 23.62, a P/E/G ratio of 1.83 and a beta of 0.57. The firm’s 50-day moving average is $302.59 and its two-hundred day moving average is $311.89. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping analysts’ consensus estimates of $4.35 by $0.13. The business had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.00 earnings per share. Equities analysts predict that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Friday, August 14th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 14th. Cencora’s payout ratio is presently 17.83%.

Cencora announced that its Board of Directors has approved a share buyback plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.